Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema

NCT06004050 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT06004050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06004050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2023
Completion date
September 12, 2025
Enrollment
362 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema